Lindau Nobel Laureate Meetings’ Post

Who do you think is California's top nonprofit in #lifesciences? Vote now ✅ https://lnkd.in/ewrA47BB Thanks for selecting us as a finalist, California Life Sciences (CLS)! Bakar Labs, the University of California, Berkeley's flagship incubator for life science startups, supports UC's mission of public service. We provide bio-entrepreneurs with lab space, facilities, and programming to enable them to move their technologies forward -- forging partnerships with our affiliates and raising funds from investors in our ecosystem. At the same time, these founders create high-value jobs, many taken by talented students coming out of UC who participate in our internship programs. We're open to companies from across the state as well as those coming from elsewhere in the US and even abroad. We're catalyzing the future of California's bioeconomy. We're part of the reason UC Berkeley 🐻🐻 is #1, #1, #1, #1, and #1 worldwide in generating venture-backed companies, founders, female entrepreneurs, female-founded startups, and capital raised by women. Help us win this Pantheon Award: Vote for Bakar Labs now! https://lnkd.in/ewrA47BB For more stories like this, follow UC Berkeley Innovation & Entrepreneurship. David Schaffer Gino Segre Saikat Chaudhuri Dawn McGee Darren Cooke Rich Lyons

Ahead of the International Day of Women and Girls in Science Day on Sunday 11th February, we are excited to introduce Dr. Belinda Cairns, Associate Director of Histopathology at Oxford BioTherapeutics. With an impressive 25-years’ experience in histopathology and tissue-based evaluation, Belinda has been an invaluable team member since joining Oxford BioTherapeutics in 2021.   Belinda leads the evaluation of protein localisation between healthy and cancerous tissue for novel drug targets, producing critical data to advance targets into the developmental and clinical phases of drug development. She shares some insights from her experience:   What inspires you about biotechnology?   “Seeing a novel protein target that you’ve worked on become a drug in the clinic, helping people overcome disease and improving their quality of life, is both amazing and motivating. Inspired by my childhood love for Sherlock Holmes, I see biotechnology as a scientific whodunnit. We follow the data, identify, investigate, and understand novel proteins, and find optimal indications for innovative drug targets.”   If you could go back and give advice to your younger self when starting your journey in STEM, what would it be?   “For women starting in STEM, my key advice is to have confidence in yourself, trust in your abilities and don’t be afraid to ask questions. Challenges may seem overwhelming, but don't take them personally. Prioritize the project, embrace and value teamwork, and remember, you don't have to be an expert in every aspect of drug discovery - harness the expertise around you.”   Join us in celebrating remarkable contributions from women involved in biotechnology and the rapidly advancing field of oncology. Let's continue to inspire and support more women and girls in science!   #WomenInScience #BiotechnologyInnovation 

We are thrilled to welcome Floris Engelhardt, PHD, to the Termeer Foundation's esteemed class of 2024 fellows. With a PhD in Physics from the Technical University of Munich and a postdoctoral tenure at MIT’s BatheBioNano lab, Floris is a visionary leader in the biotech arena.  As the driving force behind Kano Therapeutics corporate strategy and technology development, Floris is pioneering advancements in DNA nanotechnology for genetic medicine. Kano Therapeutics is redefining gene editing with their innovative circular single-stranded DNA, promising more effective genetic cures.  Their approach unlocks a safer, more flexible payload for non-viral delivery of genetic material. Her vision for Kano Therapeutics is poised to revolutionize the biotech industry by overcoming scalability bottlenecks and enabling precise, long DNA insertions. With her leadership, Kano is dedicated to patient-focused solutions, understanding the complexities of genetic diseases and the urgent need for innovative therapies. Join us in celebrating Floris Engelhardt’s remarkable achievements and her journey ahead in transforming the future of healthcare. Learn more about Floris at  https://bit.ly/4eFhT1P. #leadership #STEM #TermeerFoundation #HealthcareInnovation #RareDisease #Biotech #PatientCare #biotechnology #lifescience #peopleempoweringcures #connectionsempoweringcures #leadershipmatters #healthcare #mentorship #science #mentor #leader #ceo #lifescience #bio #TermeerFellows #womeninbiotech #womenshealth #brainawarenessmonth #alzheimersandbrainawareness

We are Monash SynBio Tech (MSBT), Monash University's pioneering student team in synthetic biology. Our multidisciplinary team spans engineering, biomedical science, molecular biology, and beyond, working to translate fundamental research into clinical applications. Our unique blend of talents allows us to approach real-world challenges from diverse perspectives, bridging the gap between synthetic biology research and tangible impacts on clinicians and patients alike. Our primary 2023 project, the Monash Melanoma Multiplex (MMM), employs CRISPR-Cas13a technology to detect abnormal microRNA expression associated with melanoma, addressing a critical issue in Australia. We are currently in our initial experimental stage where we are assessing a panel of 7 microRNAs which are known to be dysregulated in melanoma and through the CRISPR-Cas 13 system we are measuring the concentrations of the microRNAs which will be quantified using fluorescent probes. At the Australasian SynBio Challenge (2023) in Canberra, we earned 'Crowd Favourite' recognition from academics and industry experts. We hope to continue with the project this year, and work towards translating our research into a point-of-care diagnostic tool to be used in healthcare settings. To expand our impact, we aim to enhance educational outreach, diversify projects, and join larger competitions, primarily the 2024 iGEM (International Genetically Engineered Machine) competition. Through these endeavours, we aim to increase our presence and generate greater interest in synthetic biology, alongside exploring opportunities to collaborate with industry professionals. Please reach out to us if you are interested in collaborating with us! #MSBT #syntheticbiology #science #healthcare #collaboration #discovery #research

🌟 Excited to Share a Recent Small Achievement! 🌟 I’m thrilled to have earned a Certificate of Appreciation for placing 2nd in the Project Health Web 'Abstract 101' scientific abstract writing competition. This recognition is for my work on "Nanotechnology-Enhanced CRISPR/Cas9 Therapy: Approach to Regenerative Medicine." 🧬🔬 In my abstract, I explored the synergy between CRISPR/Cas9 technology and nanotechnology in regenerative medicine and cancer therapy. The integration of nanocarriers, such as lipids, nanoparticles, and polymers, plays a crucial role in enhancing the precision and effectiveness of gene editing by protecting CRISPR components and improving cellular uptake. This approach holds great promise not only in oncology but also in tackling global health challenges like antibiotic resistance. This experience has not only deepened my understanding of cutting-edge genetic engineering technologies but also contributed 7 research volunteer hours towards my ongoing commitment to advancing science. I’m grateful for this opportunity and excited to continue exploring the frontiers of regenerative medicine and genetic therapies. Thanks to the Project Health Web (Student Research Non-profit) team for organizing such an impactful competition! #ScientificResearch #GeneEditing #Biotech #Nanomedicine #STEM #Innovation #Healthcare #Genetics #TechInMedicine #MedicalBreakthrough #FutureOfMedicine #CancerResearch #GeneTherapy #MedTech #CRISPRRevolution #LifeSciences #BiomedicalEngineering #CellTherapy #ResearchInnovation #MedEd #ScienceCommunication

Ready to explore biotech innovation? ELK Biotech, dedicated to pioneering solutions driving scientific progress. 🔬 About ELK Biotech:🔬 With a focus on research, development, and distribution of high-quality biological reagents, including ELISA kits, antibodies, and molecular biology products, we empower scientists worldwide to push the boundaries of possibility in their research endeavors. 💡 Our Products:💡 From cutting-edge ELISA kits designed for precise biomarker detection to a comprehensive range of meticulously validated antibodies and advanced molecular biology tools, our product portfolio is tailored to meet the diverse needs of researchers across various fields, including immunology, oncology, neuroscience, and beyond. 🤝 Let's Collaborate:🤝 Are you seeking reliable partners in your scientific journey? Whether you're a researcher, academic institution, or biotech company, we invite you to collaborate with us. We can unlock new discoveries and make meaningful contributions to the advancement of biomedicine together. 📧 Get in Touch: 📧 Ready to embark on a partnership? Reach out to me on LinkedIn directly <tiana@elkbiotech.com> or visit our website at ELKBiotech.com to learn more about our offerings and explore how we can collaborate to accelerate scientific breakthroughs. Let's make research easier! 💪 #ELKBiotech #Biotechnology #Science #Innovation #Collaboration

🧬 Did you know that...? Celebrating Biotechnology Day 🧬 Today, 16 June, we celebrate the International Biotechnology Day, which commemorates a historic milestone that revolutionised the world: in 1971, the research team led by Chakrabarty created a genetically engineered bacterial variant, Pseudomonas putida, capable of breaking down petroleum components. This laid the foundation stone for solving environmental problems that we all care so much about, but also opened the door to countless applications of the biotechnology in medicine. Nanoligent is fighting against cancer with an approach that combines biotechnology and chemotherapy: we develop drug-protein nanoconjugates for the targeted treatment of metastatic cancer cells that enable more effective and less invasive therapies. 🔬 Innovation at Nanoligent: We use innovative nanotechnology to improve the efficacy of cancer treatments through better targeting. Just as Chakrabarty used his ingenuity to change the landscape of his time, at Nanoligent we use our research to break new ground in personalised medicine. 🌐 Looking to the future / On the shoulders of giants: Revolutionizing personalized medicine by Nanotechnology. The great work of Chakrabarty and many who came before us allows us to design solutions that both treat patients and improve their quality of life. That is why Biotechnology Day is a day to celebrate all together 🎉🍾🎈. #BiotechDay #BiotechInnovation #Nanoligent #Cancer #Nanotechnology #BiotechnologyInHealth #CancerResearch

"Exciting Update! I recently participated in a national-level article writing competition organized by Academic Decipher in collaboration with R.C. Patel Institute of Pharmaceutical Education and Research. My partner, Durgesh Suryavanshi , and I co-authored an insightful article on "The Use of Gold Nanoparticles in Cancer Diagnosis." Although we didn't make it to the final round, being shortlisted for the 2nd round was an achievement in itself! Analyzing over 50 articles was an incredible learning experience that broadened my knowledge and critical thinking skills. Key Takeaways: - Collaborative research with Durgesh Suryavanshi - In-depth analysis of gold nanoparticles in cancer diagnosis - Enhanced research and critical thinking skills Looking forward to building on this experience and exploring more innovative applications of nanotechnology! #ArticleWriting #GoldNanoparticles #CancerDiagnosis #Research #Collaboration #LearningExperience"

🌟 Exciting News in Biotechnology Innovation! 🌟 The National Science Foundation and the National Institutes of Health have teamed up to award $12.7 million across nine innovative research teams dedicated to unraveling the mysteries of RNA - a cornerstone of life's molecular machinery. RNA, though discovered nearly a century ago, still holds untapped potential that could revolutionize biotech applications. From combating diseases in crops to pioneering new cancer therapies, the possibilities are boundless. Each team, funded through the Molecular Foundations for Biotechnology program, is set to receive between $1 million to $1.65 million to explore RNA's intricate roles and potential applications. This initiative is not just about advancing science; it's about building the future of our STEM workforce. NSF's investment also emphasizes mentorship and training for students and early-career researchers, ensuring a bright future in biotech innovation. #Biotechnology #RNA #Innovation #Research #STEM #NSF #NIH 

A nice overview of Vizma!